Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
58 results about "Cell stress" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Memory device
InactiveUS20060158948A1Improve retention characteristicsCorrection for variationRead-only memoriesDigital storagePhase-change memoryVirtual cell
Disclosed are a phase change memory with improved retention characteristic of a phase change device, and a method for refreshing the phase change memory. The fact that a memory is a DRAM interface compatible memory is exploited. There are provided dummy cells stressed in accordance with the number of times of read and write operations. Changes in the resistance value of the dummy cells are detected by comparator circuits. If the resistance value have been changed beyond a predetermined reference value (that is, changed to a low resistance), a refresh request circuit requests an internal circuit, not shown, to effect refreshing. The memory cells and the dummy cells are transitorily refreshed and correction is made for variations in the programmed resistance value of the phase change devices to assure the margin as well as to improve retention characteristic.
Owner:ELPIDA MEMORY INC
Visual-servoing optical microscopy
InactiveUS20110216953A1Close monitoringOptimize culture conditionsMicrobiological testing/measurementCharacter and pattern recognitionVisual perceptionCell stress
The present invention provides methods and devices for the knowledge-based discovery and optimization of differences between cell types. In particular, the present invention provides visual servoing optical microscopy, as well as analysis methods. The present invention provides means for the close monitoring of hundreds of individual, living cells over time; quantification of dynamic physiological responses in multiple channels; real-time digital image segmentation and analysis; intelligent, repetitive computer-applied cell stress and cell stimulation; and the ability to return to the same field of cells for long-term studies and observation. The present invention further provides means to optimize culture conditions for specific subpopulations of cells.
Owner:RGT UNIV OF CALIFORNIA
Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
This invention provides a method of inhibiting the binding of a β-sheet fibril to RAGE on the surface of a cell which comprises contacting the cell with a binding inhibiting amount of a compound capable of inhibiting binding of the β-sheet fibril to RAGE so as to thereby inhibit binding of the β-sheet fibril to RAGE. In one embodiment the β-sheet fibril is amyloid fibril. In one embodiment, the compound is sRAGE or a fragment thereof. In another embodiment, the compound is an anti-RAGE antibody or portion thereof. This invention provides the above method wherein the inhibition of binding of the β-sheet fibril to RAGE has the consequences of decreasing the load of β-sheet fibril in the tissue, inhibiting fibril-induced programmed cell death, inhibiting fibril-induced cell stress. This invention also provides methods of determining whether a compound inhibits binding of a β-sheet fibril to RAGE on the surface of a cell.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
Described is a method for treating an individual having a neurological disorder with an associated mutation or mutations in a gene encoding a lysosomal enzyme. Specifically, the individual is administered a specific pharmacological chaperone for the lysosomal enzyme which increases trafficking of the protein from the ER to the lysosome in neural cells, with or without concomitantly increasing enzyme activity in neural cells. Restoration of trafficking relieves cell stress and other toxicities associated with accumulation of mutant proteins. Restoration of enzyme activity relieves substrate accumulation and pathologies associated with lipid accumulation. In a specific embodiment, the neurological disorder is Parkinson's disease or parkinsonism which is associated with mutations in glucocerebrosidase.
Owner:AMICUS THERAPEUTICS INC
Method for estimating secondary cell SOH value and testing residual service life
InactiveCN103308864AOptimize usage efficiencyEase of maintenanceElectrical testingPredictive methodsModel parameters
The invention provides a method for estimating a secondary cell SOH value and testing the residual service life and relates to a method for predicting the residual service life of a secondary cell. The predicting method comprises the following steps of acquiring performance degradation concomitant variable data of the secondary cell in real time, establishing a secondary cell degradation concomitant variable state process model and estimating model parameters in real time, calculating a degradation quantity value of the secondary cell, calculating a result and cell ex-factory data in real time, estimating a current SOH value of the secondary cell in real time, establishing a secondary cell stress-degradation united model and estimating model parameters, and calculating the residual service life of the secondary cell under different using conditions according to preset using standards of the secondary cell in real time. By means of the method for estimating the secondary cell SOH value and testing the residual service life, the accuracy and the reliability of health status SOH estimation and residual service life prediction of the secondary cell can be improved, the using and maintenance efficiency of the cell is improved, and the service life of the cell is prolonged.
Owner:NAT UNIV OF DEFENSE TECH
Therapeutic approaches for treating alzheimer's disease
InactiveUS20120270836A1Significant comprehensive benefitsLow dosBiocideNervous disorderSynapseAngiogenesis growth factor
The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s), can effectively modulate synapse function and / or angiogenesis and / or cell stress response. The invention also relates to methods of producing a drug or a drug combination for treating Alzheimer's disease and to methods of treating Alzheimer's disease or a related disorder.
Owner:PHARNEXT
Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
Owner:AMICUS THERAPEUTICS INC
Visual-servoing optical microscopy
InactiveUS7546210B2Close monitoringOptimize culture conditionsImage enhancementImage analysisVisual perceptionCell stress
Owner:RGT UNIV OF CALIFORNIA
Cell Culture Media Supplement and Method of Molecular Stress Control
InactiveUS20120028933A1High yieldFunction increaseBiocideHydroxy compound active ingredientsCell culture mediaStressor
A novel class of agents has been identified to serve as cell-guard agents and / or target-specific supplements to increase cell quality and yield, as well as select for target cell populations. Laboratory experiments have demonstrated the use of cell-guard agents and / or target-specific supplements in the bioprocessing of cells as well as in selecting out a desired cell population. Several potential additive agents (both natural and synthetic) have been identified during these studies, including Vitamin D3, NAC, resveratrol, salubrinal, AKT, and tunicamycin (among others) that hold promise for application in cell models. In one embodiment, hypothermic stress regimes are utilized. In another embodiment, normothermic conditions are utilized while other stressors are tested in the processing. The methods of maintaining mass cell cultures and / or selecting out particular cell populations for further research and clinical use represents an important step in therapeutic discovery. The cell-guard agents are process-matched and cell-matched to protect and / or select particular cells during laboratory and clinical manipulation. The components modulate cell stress and survival pathways.
Owner:CPSI HLDG
Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
Owner:PHARNEXT
Uses of labeled hsp90 inhibitors
The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6).
Owner:SLOAN KETTERING INST FOR CANCER RES +1
Memory device including a programmable resistance element
InactiveUS20090010048A1Improve featuresCorrection for variationRead-only memoriesDigital storagePhase-change memoryVirtual cell
Owner:LONGITUDE LICENSING LTD
Method of identifying substances useful for promoting resistance to cell stress
InactiveUS7306905B2Improve the immunityHigh activityCompound screeningApoptosis detectionIntegrated stress responseHigh-Throughput Screening Methods
Owner:NEW YORK UNIV
Methods of upscaling mesenchymal stromal cell production, compositions and kit thereof
InactiveUS20160002601A1Dead animal preservationSkeletal/connective tissue cellsHigh cellClinical grade
The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product / Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications. Present disclosure also discloses a robust manufacturing process for consistent production of clinical grade Mesenchymal Stromal cells (MSCs). The process enables production of highly viable potent cells. The process steps relating to preparation of media, cell seeding, harvesting are fine tuned to achieve consistency in cell yield, superior cell viability, purity, improved cell proliferation, high cell recovery, low HLA-DR expression, reduction in culture duration. The viability and purity of cells are further improved by optimized wash process without cell loss / cell stress. The disclosure further provides a method of cyrostoring MSCs at high cell density without affecting the viability of cells. It further provides economical means to store and transport at −80° C.
Owner:STEMPEUTICS RES PRIVATE
Therapeutic approaches for treating alzheimer'S disease
InactiveUS8809302B2Significant comprehensive benefitsLow dosBiocideNervous disorderSynapseAngiogenesis growth factor
Owner:PHARNEXT
Novel cucumber SNP molecular marker
InactiveCN104988142AHelp with positioningMicrobiological testing/measurementDNA/RNA fragmentationPolymorphism analysisCell stress
The invention discloses a novel cucumber SNP molecular marker. The mark number of the novel cucumber SNP molecular marker is SLAF7695. According to the novel cucumber SNP molecular marker, the simplified genome depth sequencing technology is utilized, 73100 SLAF labels are obtained totally, 5355 polymorphic markers of three types including SNP, EPSNP and INDEL are obtained through polymorphic analysis, and 140 different markers closely related to cucumber powdery mildew resistance are obtained and mainly concentrated on the first chromosome and the sixth chromosome. Two candidate areas related to powdery mildew resistance characters are successfully located, seven special markers closely linked with cucumber powdery mildew resistance are obtained, 28 genes and related annotation information are obtained through gene annotation, and five genes are related to the functions of defense response, harm response, toxin catabolism, cell stress response and the like. The novel cucumber SNP molecular marker provides a theoretical foundation for exploration of cucumber powdery mildew resisting mechanism and molecular marker assisted selective breeding.
Owner:ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES
Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
This invention provides a method of inhibiting the binding of beta-sheet fibril to RAGE on the surface of a cell which comprises contacting the cell with a binding-inhibiting amount of a compound capable of inhibiting binding of beta-sheet fibril to RAGE so as to thereby inhibit binding of beta-sheet fibril to RAGE.In one embodiment, the beta-sheet fibril is amyloid fibril. In one embodiment, the compound is sRAGE or a fragment thereof. In another embodiment, the compound is an anti-RAGE antibody or portion thereof.This invention provides the above method wherein the inhibition of binding of the beta-sheet fibril to RAGE has the consequences of decreasing the load of beta-sheet fibril in the tissue, inhibiting fibril-induced programmed cell death, and inhibiting fibril-induced cell stress.This invention also provides methods of determining whether a compound inhibits binding of a beta-sheet fibril to RAGE on the surface of a cell.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Microarray chip for detecting protein expression in cell stress reaction and its preparation method, kit and detection method
The invention discloses a microarray chip for detecting protein expression in a cell stress reaction and its preparation method, kit and detection method. The microarray chip comprises seven stress reaction markers, can ensure inner cell protein expression change corresponding to a cell stress reaction under different stimulation conditions and realizes fast screening and evaluation. A hydroformylation-modified glass sheet is used as a solid carrier so that specific antibody bonding is stable and activity is high. The microarray chip can effectively eliminate the false positive and false negative results of the spectral chip test. The cross-reaction test result shows that the microarray chip has high index detection sensitivity and good specificity. The preparation method has simple processes, realizes fast detection, finishes the whole process in 2d, has high sensitivity and good specificity, realizes a low production cost and has a wide industrialization prospect.
Owner:广东南芯医疗科技有限公司
Ocean ecologic toxicology research platform based on microfluidic chip
InactiveCN108504569AEasy to operateLow costLaboratory glasswaresTissue/virus culture apparatusMulti responseConcentration gradient
Owner:DALIAN UNIV
Protein related to cell stress, and coding gene and application thereof
InactiveCN101967187AEffective treatment repairPeptide/protein ingredientsMicroorganismsStress conditionsApoptosis
The invention discloses a protein related to cell stress, and a coding gene and application thereof. The protein is 1) a protein which has an amino acid sequence shown as a sequence 2 in a sequence table, or 2) a protein which is related to the cell stress and derived from the protein 1) with the amino acid sequence shown as the sequence 2 in the sequence table by substituting and / or losing and / or adding one or more amino acid residues. Cells which overexpress an OCT4B-190 protein are constructed; results prove that the apoptosis of the cells which overexpress the OCT4B-190 protein under the stress condition is obviously reduced, namely the OCT4B-190 is the protein related to the cell stress; and the OCT4B-190 protein and the coding gene thereof can be used for inhibiting cell apoptosis under the stress condition.
Owner:INST OF GENETICS & DEVELOPMENTAL BIOLOGY CHINESE ACAD OF SCI
Composition for improving skin stress response and promoting probiotics balance and forming method
InactiveCN108403502AImprove fragile issuesEasy to prepareCosmetic preparationsToilet preparationsAlpha-glucan oligosaccharideIrritation
The invention discloses a composition for improving skin stress response and promoting probiotics balance and a forming method. The composition is prepared from an artemisia annua leaf extract, a lactobacillus and eriodictyon californicum fermentation product extract, alpha-glucan oligosaccharide, carnosine and 1,2-pentanediol, wherein the concentration of the artemisia annua leaf extract is between 5% and 80%; the concentration of the lactobacillus and eriodictyon californicum fermentation product extract is 5% to 80%; the concentration of the alpha-glucan oligosaccharide is between 5% and 80%; the concentration of the carnosine is between 5% and 80%; the concentration of the 1,2-pentanediol is between 5% and 80%. Not only can the problem of skin fragility caused by deficiency of stratumcorneum and injuries be alleviated, but also the damage to the skin barrier caused by external stimuli can be solved; by combining various components, the skin can immediately improve cell stress response per self after being damaged to resist external irritation and damage, so that use feeling is good, the effect is fast, the preparation method is simple, and the composition is suitable for large-scale production and gives no burden to the skin.
Owner:上海上水和肌化妆品有限公司
Therapeutic approaches for treating alzheimer's disease
ActiveUS20140357648A1Effectively affect pathway involved in ADSulfonylurea active ingredientsAmide active ingredientsSynapseAngiogenesis growth factor
The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s), can effectively modulate synapse function and / or angiogenesis and / or cell stress response. The invention also relates to methods of producing a drug or a drug combination for treating Alzheimer's disease and to methods of treating Alzheimer's disease or a related disorder.
Owner:PHARNEXT
Visual-servoing optical microscopy
InactiveUS8548745B2Close monitoringOptimize culture conditionsMicrobiological testing/measurementCharacter and pattern recognitionVisual perceptionCell stress
Owner:RGT UNIV OF CALIFORNIA
Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
Owner:PHARNEXT
A method of determining or predicting a characteristic of a cell
ActiveCN105518458ABioreactor/fermenter combinationsBiological substance pretreatmentsCell featureCell stress
Owner:VALITACELL
Electricity-force stimulating cell culture apparatus
InactiveCN104745471AGood biocompatibilityRealistically simulate the stress environmentTissue/virus culture apparatusStress based microorganism growth stimulationElectrical impulseBiology
The invention provides an electricity-force stimulating cell culture apparatus, which comprises a cell cultivator and a signal generator, wherein the cell cultivator comprises a cultivator base; a conductive film is arranged on the cultivator base; an electricity-force stimulating electrode plate is arranged above the cell cultivator, and comprises an electricity-force stimulating electrode base on the upper part, a conductive layer on the middle part and a piezoelectric stimulator on the lower part; and a positive electrode and a negative electrode of the signal generator are respectively connected with the conductive layer on the electricity-force stimulating electrode plate and the conductive film on the cell cultivator. When cell cultivation is carried out, electric pulse stimulation can be provided for cells and a culture medium in the cell cultivator; after the piezoelectric stimulator of the electricity-force stimulating electrode plate is electrified, micro-vibration can be generated under the action of current, and the force stimulation equivalent to peripheral cell peristalsis in a living body is provided for the cells. The electricity-force stimulating cell culture apparatus is capable of really simulating the cell stress environment in the living body; and an environment which is relatively close to cell growth environment in the living body is provided for in vitro culture of the cells.
Owner:HENAN POLYTECHNIC UNIV
Preparation method of natural scorpion venom polypeptide and application of natural scorpion venom polypeptide to bone marrow haematopoietic functional protection
InactiveCN104725498AProven new medicinal usesPeptide/protein ingredientsPeptide preparation methodsTotal amino acidsButhus
The invention discloses a natural scorpion venom polypeptide. The natural scorpion venom polypeptide is a novel protein separated from scorpion venom of Buthus martensii Karsch and has a novel medicinal purpose on the aspect of bone marrow haematopoietic functional protection. A preparation method of the natural scorpion venom polypeptide comprises the following steps of (1) collecting the scorpion venom of Buthus martensii Karsch; (2) separating SVPIV; (3) purifying BmKpp; (4) measuring the molecular weight and amino acid sequence of of BmKpp; and (5) measuring the bone marrow haematopoietic functional protection effect of BmKpp. BmKpp is a novel polypeptide from scorpion venom of Buthus martensii Karsch and has a remarkable bone marrow haematopoietic functional protection effect. BmKpp is single in component, precise in molecular weight, clear in total amino acid sequence, remarkable in cell proliferation promoting effect as well as standard and controllable in quality in the purification process so as to be beneficial to large-scale production. BmKpp has remarkable advantages and prospects on the aspects of bone marrow haematopoietic functional protection and development of drugs for preventing / protecting cell stress injury (radiotherapy, chemotherapy and the like).
Owner:孔天翰 +2
Method for diagnosing or treating tumors using sphingomyelin containing liposomes
The invention provides compositions and methods for diagnosing tumors and augmentic therapeutic intervention and measuring response to cell stress using sphingomyelin containing liposomes. The liposomes can include radiotracers, contrast agents, chromophores, dyes, enzyme substrates, therapeutic agents, chemotherapeutic agents or DNA segments. The indicators enable measurement of the extent of cellular release of Acid SMase at a localized site of cell stress. The nanoparticles have the capacity to locally release their contents, be it imaging (for diagnosis) or therapeutic agents (to augment therapy).
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Therapeutic approaches for treating Alzheimer's disease
ActiveUS9387206B2Peptide/protein ingredientsSulfonylurea active ingredientsSynapseAngiogenesis growth factor
Owner:PHARNEXT
Micro-fluidic chip and manufacturing method thereof
PendingCN112538430AAchieve extrusionImprove controllabilityBioreactor/fermenter combinationsBiological substance pretreatmentsEngineeringMechanical engineering
The embodiment of the invention discloses a micro-fluidic chip and a manufacturing method thereof. The micro-fluidic chip comprises a pressurization layer comprising a vent hole and a vent groove, wherein the vent hole is used for introducing gas into the vent groove, and the vent groove generates a gas pressure based on the introduced gas; a capture layer comprising a capture channel that is usedfor introducing a plurality of samples to be pressurized; and a deformation layer arranged between the pressurization layer and the capture layer and used for generating deformation according to theair pressure so as to apply mechanical force to the plurality of samples to be pressurized in the capture layer. According to the micro-fluidic chip provided by the embodiment of the invention, cell spheres are extruded through the capture layer, the deformation layer and the pressurization layer, and the extrusion force on cells can be controlled by controlling the pressure of gas introduced by the pressurization layer, so that the controllability of cell stress is realized.
Owner:SOUTH UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com